The Singapore facility is part of Sanofi's 900 million euro investment to develop two new EVFs globally over five years. The ...

In a bid to bolster pandemic preparedness, Sanofi has opened a modular vaccine manufacturing plant in Tuas Biomedical Park, ...

The 58,000 sq m plant – Sanofi’s second factory in Singapore – will produce vaccines and other biopharmaceutical products ...

Sanofi SA added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest ...

The facility, named Modulus, can be adapted to manufacture up to four vaccines or biopharmaceuticals at the same time, and ...

The French pharma firm is seeking to increase insulin production in Beijing as trade tensions between the EU and China simmer ...

Sanofi's $595m Singapore facility, Modulus, leverages advanced technology for rapid, flexible vaccine production, bolstering ...

The Singapore facility is part of Sanofi's 900 million euro investment to develop two new EVFs globally over five years. The other facility is in Neuville-sur-Saône, France. SINGAPORE — French ...